A phase I single ascending dose (SAD) trial of SAGE 718 in healthy volunteers.

Trial Profile

A phase I single ascending dose (SAD) trial of SAGE 718 in healthy volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Nov 2017

At a glance

  • Drugs SAGE 718 (Primary)
  • Indications Smith-Lemli-Opitz syndrome
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Most Recent Events

    • 02 Nov 2017 Status changed from recruiting to completed, according to a Sage Therapeutics media release.
    • 27 Apr 2017 Status changed from planning to recruiting according to a SAGE Therapeutics media release.
    • 16 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top